We are proud to announce that CureDiab has been awarded a Eurostars grant for the STOP-MASH project. In collaboration with partners from the Netherlands and Germany, the project aims to advance the pre-clinical development of HK3, a first-in-class small molecule targeting novel GABA-A receptor mechanisms for the treatment of MASH. Supported by Eurostars—a joint initiative of EUREKA and the European Commission—the project will leverage cutting-edge Liver-on-Chip model and innovative fibrosis biomarkers, to validate the efficacy of this promising new therapeutic approach.